目的:探讨新辅助化疗对乳腺癌人表皮生长因子受体-2(Cerb-B2)表达的影响及Cerb-B2的变化与新辅助化疗临床疗效的相关性,从而明确新辅助化疗后Cerb-B2表达改变的临床意义。方法:选取2010年至2012年经空心针穿刺病理诊断明确的乳腺癌患者70例予以新辅助化疗,通过免疫组化法分别检测化疗前后乳腺癌组织中Cerb-B2的表达。化疗方案(TT方案):多西紫杉醇(艾素)70 mg·m-2第1天,吡柔比星60 mg第1天,21 d为1个周期,经过2~4个周期新辅助化疗,评估化疗疗效,再行乳腺癌改良根治术或保乳手术,比较化疗前后Cerb-B2表达的变化,分析Cerb-B2表达的变化与化疗疗效的相关性。结果:70例乳腺癌新辅助化疗病例中,化疗前后Cerb-B2均过度表达13例(A组);化疗前过度表达,化疗后未过度表达16例(B组);化疗前未过度表达,化疗后过度表达7例(C组);化疗前后均未过度表达34例(D组)。新辅助化疗前后Cerb-B2的表达差异有统计学意义(P<0.05),Cerb-B2过度表达和未过度表达患者疗效比较差异无统计学意义(P=1.0)。4个亚组间疗效比较差异无统计学意义(P=0.589)。结论:新辅助化疗能改变Cerb-B2的表达状态,但是新辅助化疗疗效与乳腺癌患者的Cerb-B2表达状态无明显相关性,同时新辅助化疗前后Cerb-B2的改变与疗效亦无明显相关性。 Objective: To investigate the effect of neoadjuvant chemotherapy on the expression of human epidermal growth factor receptor-2 (Cerb-B2) and the relationship between the changes of Cerb-B2 and the clinical efficacy of neoadjuvant chemotherapy, so as to clarify the effect of neoadjuvant chemotherapy on the expression of Cerb-B2 The clinical significance of altered expression. Methods: Seventy patients with breast cancer diagnosed by needle aspiration were selected for neoadjuvant chemotherapy from 2010 to 2012. The expression of Cerb-B2 in breast cancer tissues before and after chemotherapy was detected by immunohistochemistry. Chemotherapy regimen (TT regimen): Docetaxel (Alzheimer’s) 70 mg · m-2 on day 1, pirarubicin 60 mg on day 1, 21 d for 1 cycle, after 2 to 4 cycles of neoadjuvant chemotherapy , To evaluate the curative effect of chemotherapy, and then to modified radical mastectomy or breast conserving surgery. The changes of Cerb-B2 expression before and after chemotherapy were compared. The correlation between the changes of Cerb-B2 expression and the curative effect of chemotherapy was analyzed. Results: In the 70 cases of neoadjuvant chemotherapy for breast cancer, Cerb-B2 was overexpressed in 13 cases before and after chemotherapy (group A), overexpressed before chemotherapy, and not overexpressed in 16 cases after chemotherapy (group B) After chemotherapy, 7 cases were overexpressed (group C), 34 cases were not overexpressed before and after chemotherapy (group D). Cerb-B2 expression was significantly different between before and after neoadjuvant chemotherapy (P <0.05). There was no significant difference in the therapeutic effect between Cerb-B2 overexpression and non-overexpression (P = 1.0). There was no significant difference in efficacy between the 4 subgroups (P = 0.589). Conclusions: Neoadjuvant chemotherapy can change the expression of Cerb-B2, but the effect of neoadjuvant chemotherapy is not correlated with the expression of Cerb-B2 in patients with breast cancer. The change of Cerb-B2 before and after neoadjuvant chemotherapy is not related to the curative effect Sex.